OmniScience and INmune Bio have partnered to utilize OmniScience’s AI-powered platform, Vivo, in INmune Bio’s Phase 2 Alzheimer’s disease clinical trial (AD02). Vivo will centralize and analyze the trial’s extensive data in real time, offering immediate insights to improve decision-making and expedite the typically lengthy trial management process. This partnership aims to revolutionize clinical trial operations by leveraging AI for enhanced efficiency and improved patient outcomes.
This collaboration is significant for both companies and the Alzheimer’s research field. For INmune Bio, Vivo provides a critical tool for analyzing complex cognitive data from a large, global trial, potentially accelerating the development of much-needed Alzheimer’s treatments. For OmniScience, this partnership offers valuable real-world application and feedback for Vivo’s ongoing development, solidifying its position as a leader in AI-driven clinical trial solutions. For the broader field, this partnership demonstrates the potential of AI to transform clinical research, leading to faster, more efficient trials and ultimately, quicker access to innovative therapies for patients.
Vivo integrates data from various sources, including electronic data capture (EDC), clinical trial management systems (CTMS), patient-reported outcomes (PROs), and lab results. Its advanced cognitive architecture combines ontological knowledge of trial protocols with clinical expertise, enabling comprehensive qualitative and quantitative data analysis. The AD02 trial has enrolled 208 patients with early Alzheimer’s disease and biomarkers of neuroinflammation. Top-line cognitive results are expected in the second quarter of 2025. The initial rollout of Vivo has already yielded significant benefits, demonstrating its capacity to translate complex data into actionable insights rapidly.
This partnership signals a shift towards smarter, AI-driven solutions in clinical trials. The integration of Vivo in INmune Bio’s AD02 trial paves the way for faster data analysis, more informed decision-making, and potentially accelerated drug development. The real-time insights offered by Vivo could significantly reduce the time it takes to bring new Alzheimer’s treatments to market, offering hope to patients and their families. The continued collaboration between OmniScience and INmune Bio will likely drive further advancements in Vivo’s capabilities, shaping the future of clinical trial management and ultimately improving patient care. The success of this partnership could encourage wider adoption of AI-powered platforms in clinical research across various therapeutic areas.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
